Literature DB >> 9120544

Chemotherapeutic induction of long-term remission in metastatic medulloblastoma.

E Leo1, P G Schlegel, A Lindemann.   

Abstract

The treatment of extraneural metastatic medulloblastoma is mainly a domain of chemotherapy. Although previous results were promising, the overall poor prognosis high relapse rates and the still unknown ideal combination of chemotherapeutic agents leave many questions open. In this study, the effectiveness of previously used chemotherapeutic agents for the treatment of metastatic medulloblastoma is reviewed, and the effectiveness and complexity of emerging new treatment strategies including high-dose chemotherapy with bone marrow and peripheral blood stem-cell transplantation are discussed. Furthermore, we describe a case of bone-metastasized recurrent medulloblastoma with the longest remission ever reported (120 months) after regimens containing doxorubicine, vincristine, cyclophosphamide (ACO-protocol) [1, 2] and methotrexate. When relapse with bone and bone marrow infiltration occurred, a second chemotherapeutically induced complete remission was achieved. High-dose-chemotherapy with autologous peripheral blood stem-cell transplantation was used as a consolidating regimen. Complete remission has persisted for over 15 months now.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9120544     DOI: 10.1023/a:1005721510659

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  27 in total

1.  Adjuvant chemotherapy for medulloblastoma: the first multi-centre control trial of the International Society of Paediatric Oncology (SIOP I).

Authors:  D M Tait; H Thornton-Jones; H J Bloom; J Lemerle; P Morris-Jones
Journal:  Eur J Cancer       Date:  1990-04       Impact factor: 9.162

2.  The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone.

Authors:  A E Evans; R D Jenkin; R Sposto; J A Ortega; C B Wilson; W Wara; I J Ertel; S Kramer; C H Chang; S L Leikin
Journal:  J Neurosurg       Date:  1990-04       Impact factor: 5.115

3.  Treatment of early recurrent medulloblastoma in children with cisplatin and etoposide: a preliminary report.

Authors:  H Kudo; T Kokunai; K Kuwamura; N Tamaki; H Sawa; I Izawa; S Tatsumi; S Hamano; S Matsumoto
Journal:  Childs Nerv Syst       Date:  1992-05       Impact factor: 1.475

4.  Medulloblastoma: freedom from relapse longer than 8 years--a therapeutic cure?

Authors:  M G Belza; S S Donaldson; G K Steinberg; R S Cox; P H Cogen
Journal:  J Neurosurg       Date:  1991-10       Impact factor: 5.115

5.  Medulloblastoma in adulthood: prognostic factors influencing survival and recurrence.

Authors:  M P Aragonés; R Magallón; C Piqueras; L Ley; J Vaquero; G Bravo
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

6.  Platinum-based chemotherapy for recurrent CNS tumours in young patients.

Authors:  E Douek; J E Kingston; J S Malpas; P N Plowman
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-08       Impact factor: 10.154

Review 7.  Medulloblastoma in adulthood.

Authors:  L Ferrante; L Mastronardi; P Celli; M Acqui; L Cervoni; A Fortuna
Journal:  J Neurosurg Sci       Date:  1991 Jan-Mar       Impact factor: 2.279

8.  Treatment of children with progressive or recurrent brain tumors with carboplatin or iproplatin: a Pediatric Oncology Group randomized phase II study.

Authors:  H S Friedman; J P Krischer; P Burger; W J Oakes; B Hockenberger; M D Weiner; J M Falletta; D Norris; A H Ragab; D H Mahoney
Journal:  J Clin Oncol       Date:  1992-02       Impact factor: 44.544

9.  Cisplatin, ara-C and etoposide (PAE) in the treatment of recurrent childhood brain tumors.

Authors:  B J Corden; L C Strauss; T Killmond; B S Carson; M D Wharam; A J Kumar; S Piantadosi; P A Robb; P C Phillips
Journal:  J Neurooncol       Date:  1991-08       Impact factor: 4.130

10.  Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II.

Authors:  C C Bailey; A Gnekow; S Wellek; M Jones; C Round; J Brown; A Phillips; M K Neidhardt
Journal:  Med Pediatr Oncol       Date:  1995-09
View more
  6 in total

1.  SPARC mediates Src-induced disruption of actin cytoskeleton via inactivation of small GTPases Rho-Rac-Cdc42.

Authors:  Praveen Bhoopathi; Christopher S Gondi; Meena Gujrati; Dzung H Dinh; Sajani S Lakka
Journal:  Cell Signal       Date:  2011-07-23       Impact factor: 4.315

2.  Shunt-related abdominal metastases in an infant with medulloblastoma: long-term remission by systemic chemotherapy and surgery.

Authors:  A Fiorillo; G Maggi; A Martone; R Migliorati; R D'Amore; E Alfieri; N Greco; S Cirillo; I Marano
Journal:  J Neurooncol       Date:  2001-05       Impact factor: 4.130

3.  Extraneural metastatic medulloblastoma in an adult.

Authors:  Merideth M Wendland; Dennis C Shrieve; Gordon A Watson; Steven S Chin; Deborah T Blumenthal
Journal:  J Neurooncol       Date:  2006-04-06       Impact factor: 4.130

4.  Suppression of uPAR retards radiation-induced invasion and migration mediated by integrin β1/FAK signaling in medulloblastoma.

Authors:  Arun Kumar Nalla; Swapna Asuthkar; Praveen Bhoopathi; Meena Gujrati; Dzung H Dinh; Jasti S Rao
Journal:  PLoS One       Date:  2010-09-24       Impact factor: 3.240

Review 5.  Progress and problems in the application of focused ultrasound for blood-brain barrier disruption.

Authors:  Natalia Vykhodtseva; Nathan McDannold; Kullervo Hynynen
Journal:  Ultrasonics       Date:  2008-04-14       Impact factor: 2.890

6.  Valproic acid induces p21 and topoisomerase-II (alpha/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines.

Authors:  Chandra M Das; Dolly Aguilera; Hernan Vasquez; Preethi Prasad; Ming Zhang; Johannes E Wolff; Vidya Gopalakrishnan
Journal:  J Neurooncol       Date:  2007-05-30       Impact factor: 4.130

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.